PVTTF Pivotal Therapeutics Inc (CE)

WOODBRIDGE, ON, March 6, 2013 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on optimizing Omega-3
therapy for cardiovascular disease and overall health, is pleased to
announce it will exhibiting at the American College of Cardiology's 62^nd Annual Scientific Session and EXPO (ACC), March 9-11, 2013 at the
Moscone Center in San Francisco, California, Booth # S2544. The ACC is
the largest gathering of cardiovascular products and services, with the
latest advances and solutions in cardiovascular science and care.

"With more that 13,000 cardiovascular professionals attending the ACC,
it is a perfect venue to showcase VASCAZEN^® the only prescription Omega-3 therapy specifically formulated for the
correction of an Omega-3 deficiency in cardiovascular patients," said
Dr. George Jackowski, Chairman and Chief Scientific Officer.  "Pivotal
will have an opportunity to educate attendees on the benefits patients
see as a result of correcting an Omega-3 deficiency with VASCAZEN^®."

About Pivotal Therapeutics Inc.


With offices in Toronto, Canada and Boca Raton, Florida, Pivotal
Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX: PVO) specialty
pharmaceutical company with a focus on cardiovascular disease and
overall health.  Pivotal Therapeutics' lead product VASCAZEN^® is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications.

VASCAZEN^® is a prescription only Medical Food specifically formulated for the
dietary management of an Omega-3 deficiency in cardiovascular patients.
VASCAZEN^® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign patents.
This unique formulation provides the cornerstone upon which a family of
cutting edge combination products, with efficacy across a broad
spectrum of cardiac care, will be commercialized.

OMAZEN^TM is a prescription grade Omega-3 providing >90% total Omega-3 in each
capsule with a unique 6:1 ratio of EPA:DHA. OMAZEN^TM is a patented product available for sale and distribution in Canada.

Disclosure Notice



The information contained in this document is as of March 6, 2013. This
press release contains forward-looking statements. Such forward-looking
statements are subject to a number of risks, assumptions and
uncertainties that could cause Pivotal's actual results to differ
materially from those projected in such forward-looking statements.
These statements can be identified by the use of words such as "will",
"anticipate", "estimate", "expect", "project", "forecast", "intend",
"plan", "believe", "project", "potential", and similar expressions with
any discussion of future operating or financial performance or events.
In particular, factors that could cause actual results to differ
materially from those in forward looking statements include the
following: Pivotal's inability to obtain additional financing on
acceptable terms; growth in costs and expenses; inability to compete
with others who provide comparable products; risk that the Company's
products will not gain widespread market acceptance; risks relating to
the Company's ability to maintain its CSNX listing. Forward-looking
statements speak only as of the date made and are not guarantees of
future performance. The Company undertakes no obligation to publicly
update or revise any forward-looking statements contained in this
document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.

SOURCE Pivotal Therapeutics Inc.